Therapy
Research And Development
Health

Sangamo Therapeutics

$9.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.31 (3.49%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell SGMO and other stocks, options, ETFs, and crypto commission-free!

About

Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. Read More The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Employees
302
Headquarters
Richmond, California
Founded
1995
Market Cap
908.45M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
2.21M
High Today
$9.27
Low Today
$8.76
Open Price
$8.99
Volume
557.44K
52 Week High
$22.90
52 Week Low
$6.26

Collections

Therapy
Research And Development
Health
Biotechnology
Engineering
Technology

News

Yahoo FinanceMar 19

Edited Transcript of SGMO earnings conference call or presentation 28-Feb-19 10:00pm GMT

Q4 2018 Sangamo Therapeutics Inc Earnings Call RICHMOND Mar 19, 2019 (Thomson StreetEvents) -- Edited Transcript of Sangamo Therapeutics Inc earnings conference call or presentation Thursday, February 28, 2019 at 10:00:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Adrian Woolfson Sangamo Therapeutics, Inc. - EVP of Research an...

109
Seeking AlphaMar 13

March Outlook For Sangamo Therapeutics

Sangamo Therapeutics (SGMO) price action continues to trade within the downward channel that has been in play since September 2018. SGMO has continued to feel the effects of the poor performance in the MPS clinical trials of its proposed medication for the treatment of Hunter's syndrome.

342
Yahoo FinanceMar 12

What Type Of Shareholder Owns Sangamo Therapeutics, Inc.’s (NASDAQ:SGMO)?

The big shareholder groups in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Companies that have been privatized tend to have low insider ownership. Sangamo Therapeutics isn’t enormous, but it’s not particularly small either. It has a market capitalization of US$1.0b, which means it would generally expect to see some institutions on the share registry. In th...

68

Earnings

-$0.23
$0.01
$0.24
$0.48
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.